Migraine is a condition that affects over 40 million individuals in the US and approximately 10% of the global population. Calcitonin gene-related peptide (CGRP) is a well-documented migraine trigger. We know this because CGRP levels are elevated in migraine, and when given CGRP, migraine patients show a delayed migraine like headache compared to control subjects who only have a mild headache. Currently my work in the Russo lab is in looking at the effects of cannabinoids in a pre-clinical model of migraine. I am also looking at the effects that cannabinoids can have on immune cells in the dura matter of the meninges.